Can anti-aging breakthroughs add 10 healthy years to the human life span? Sam Altman, the CEO of OpenAI is paying to find out.
When a startup called Retro Biosciences eased out of stealth mode in mid-2022, it announced it had secured $180 million to bankroll an audacious mission: to add 10 years to the average human life span. It had set up its headquarters in a raw warehouse space near San Francisco just the year before, bolting shipping containers to the concrete floor to quickly make lab space for the scientists who had been enticed to join the company.
Retro said that it would “prize speed” and “tighten feedback loops” as part of an “aggressive mission” to stall aging, or even reverse it. But it was vague about where its money had come from. At the time, it was a “mysterious startup,” according to press reports, “whose investors remain anonymous.”
Now MIT Technology Review can reveal that the entire sum was put up by Sam Altman, the 37-year-old startup guru and investor who is CEO of OpenAI.
Read More at MIT Technology Review
Read the rest at MIT Technology Review